Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 1008-1016

  Guo, Wen Zhi ^a   Wang, Yanwen ^b   Umeda, Eri ^b   Shiina, Isamu ^b   Dan, Shingo ^a   Yamori, Takao ^a,c  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

Anti cancer; Drug discovery; JFCR39 panel; Novel mechanism; Ridaifen; Tamoxifen derivative

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; RIDAIFEN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN JFCR39; CONTROLLED STUDY; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 84878819172     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00129     Document Type: Article

References (32)

1. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat. Med., 2, 381-385 (1996).
2. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol., 7, 1266-1274 (1993).
3. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31, 41-52 (1994).
4. Catherino WH, Jordan VC. A risk-benefit assessment of tamoxifen therapy. Drug Saf., 8, 381-397 (1993).
5. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 97, 1652-1662 (2005).
6. McDonnell DP. The Molecular Pharmacology of SERMs. Trends Endocrinol. Metab., 10, 301-311 (1999).
7. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 6, 469-477 (2001).
8. Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem., 277, 45695-45703 (2002).
9. Shiina I, Sano Y, Nakata K, Kikuchi T, Sasaki A, Ikekita M, Hasome Y. Synthesis of the new pseudo-symmetrical tamoxifen derivatives and their anti-tumor activity. Bioorg. Med. Chem. Lett., 17, 2421-2424 (2007).
10. Shiina I, Sano Y, Nakata K, Kikuchi T, Sasaki A, Ikekita M, Nagahara Y, Hasome Y, Yamori T, Yamazaki K. Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. Biochem. Pharmacol., 75, 1014-1026 (2008).
11. Yamori T. Panel of human cancer cell lines provides valuable data-base for drug discovery and bioinformatics. Cancer Chemother. Pharmacol., 52 (Suppl. 1), S74-S79 (2003).
12. Nakatsu N, Nakamura T, Yamazaki K, Sadahiro S, Makuuchi H, Kanno J, Yamori T. Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol. Pharmacol., 72, 1171-1180 (2007).
13. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res., 62, 1139-1147 (2002).
14. Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res., 59, 4004-4011 (1999).
15. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res., 59, 4042-4049 (1999).
16. Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res., 70, 4982-4994 (2010).
17. Kong D, Dan S, Yamazaki K, Yamori T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur. J. Cancer, 46, 1111-1121 (2010).
18. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst., 98, 545-556 (2006).
19. Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. J. Biol. Chem., 287, 3885-3897 (2012).
20. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990).
21. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83, 757-766 (1991).
22. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst., 81, 1088-1092 (1989).
23. Eglen RM. Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev. Technol., 1, 97-104 (2002).
24. Wallace S, Yang DJ, Deplessand E, Cherif A, Quadri S. High affinity tamoxifen derivatives. US6096874 (2000).
25. Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem. Biol., 8, 427-436 (2001).
26. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause, 10, 433-439 (2003).
27. Wallace OB, Richardson TI, Dodge JA. Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity. Curr. Top. Med. Chem., 3, 1663-1682 (2003).
28. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res., 61, 8412-8415 (2001).
29. Lewiecki EM. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther. Clin. Risk Manag., 5, 817-827 (2009).
30. Mountfield RJ, Kiehr B, John BA. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Metab. Dispos., 28, 503-513 (2000).
31. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J. Clin. Endocrinol. Metab., 86, 755-760 (2001).
32. Rivera-Guevara C, Camacho J. Tamoxifen and its new derivatives in cancer research. Recent Patents Anticancer. Drug Discov., 6, 237-245 (2011).